🔴 Xenetic Biosciences is trading 6% down today amid proposed Santersus acquisition uncertainty

Xenetic Biosciences is trading 6.02% down at $2.81 amid volatility surrounding its proposed all-stock acquisition of Santersus AG.

• Santersus holders would receive approximately 85% of the combined company; existing Xenetic shareholders, about 15%. The deal requires shareholder approval and is expected to close in the fourth quarter of 2026.
• Sharp volatility included gains on September 17, September 18, and September 21, after a 48.71% drop on September 16.
• Broader markets are modestly higher, so company-specific transaction concerns appear dominant.